Journal of virology2000; 74(7); 3112-3121; doi: 10.1128/jvi.74.7.3112-3121.2000

Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.

Abstract: Equine infectious anemia virus (EIAV) infection of horses is characterized by recurring cycles of disease and viremia that typically progress to an inapparent infection in which clinical symptoms are absent as host immune responses maintain control of virus replication indefinitely. The dynamics of EIAV viremia and its association with disease cycles have been well characterized, but there has been to date no comprehensive quantitative analyses of the specific tissue sites of EIAV infection and replication in experimentally infected equids during acute disease episodes and during asymptomatic infections in long-term inapparent carriers. To characterize the in vivo site(s) of viral infection and replication, we developed a quantitative competitive PCR assay capable of detecting 10 copies of viral DNA and a quantitative competitive reverse transcription-PCR assay with a sensitivity of about 30 copies of viral singly spliced mRNA. Animals were experimentally infected with one of two reference viruses: the animal-passaged field isolate designated EIAV(Wyo) and the virulent cell-adapted strain designated EIAV(PV). Tissues and blood cells were isolated during the initial acute disease or from asymptomatic animals and analyzed for viral DNA and RNA levels by the respective quantitative assays. The results of these experiments demonstrated that the appearance of clinical symptoms in experimentally infected equids coincided with rapid widespread seeding of viral infection and replication in a variety of tissues. During acute disease, the predominant cellular site of viral infection and replication was the spleen, which typically accounted for over 90% of the cellular viral burden. In asymptomatic animals, viral DNA and RNA persisted in virtually all tissues tested, but at extremely low levels, a finding indicative of tight but incomplete immune control of EIAV replication. During all disease states, peripheral blood mononuclear cells (PBMC) were found to harbor less than 1% of the cellular viral burden. These quantitative studies demonstrate that tissues, rather than PBMC, constitute the predominant sites of virus replication during acute disease in infected equids and serve as resilient reservoirs of virus infection, even in the presence of highly effective immune responses that maintain a stringent control of virus replication in long-term inapparent carriers. Thus, these observations with EIAV, a predominantly macrophage-tropic lentivirus, highlight the role of tissues in sequestering lentiviral infections from host immune surveillance.
Publication Date: 2000-03-09 PubMed ID: 10708426PubMed Central: PMC111810DOI: 10.1128/jvi.74.7.3112-3121.2000Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the specific sites in horses’ bodies where the Equine infectious anemia virus (EIAV) thrives and replicates during both acute outbreaks and periods of asymptomatic infection. The researchers used advanced methods to detect and quantify the virus in various tissues and blood cells, identifying the spleen as the primary site of infection and replication during acute disease while virtually all tissues harbored low virus levels in asymptomatic animals.

Objective and Methodology

  • The primary aim of the research was to identify the explicit tissue sites of EIAV infection and replication as this was overlooked in prior research. The researchers sought clarity on these areas to understand the virus better and potentially develop targeted treatment methods.
  • Two distinct quantitative assays were established by the researchers for the study, a quantitative competitive PCR assay and a quantitative competitive reverse transcription-PCR assay. These assays were created to detect the presence and quantity of viral DNA and RNA.
  • The subjects of the experiment, equids (horses and alike), were infected with two different versions of the virus for the experiment, namely EIAV(Wyo) and EIAV(PV).
  • Various tissues and blood cells were then isolated from the animals during the periods of acute disease and asymptomatic illness. These samples were analyzed for viral DNA and RNA levels using the two quantitative assays developed.

Key Findings

  • During the phase of acute disease, the research found that the virus efficiently spread and replicated in various tissues. The spleen was identified as the most common site, accounting for over 90% of the viral burden in cells. This indicates that the spleen is a primary site for EIAV infection and replication during periods of acute disease.
  • In the case of asymptomatic animals, the researchers found that the virus’ DNA and RNA persisted in practically all examined tissues, though at extremely low levels, suggesting a strong but not entirely perfect immune control of EIAV replication.
  • The study emphasized that tissues serve as the dominant sites for virus replication during acute disease and seemingly resilient reservoirs of virus infection, even amidst highly effective immune responses. In contrast, the role of peripheral blood mononuclear cells (PBMCs) in harboring the virus was determined to be minimal, accounting for less than 1% of the cellular viral burden.

Conclusion and Implications

  • The research, therefore, deduced that, similar to other lentiviruses that primarily target macrophages, EIAV uses tissues to hide from the host’s immune responses. This highlights the significant role tissues play in sustaining lentiviral infections despite the host’s robust immune reaction.
  • The evidence generated through this study can potentially guide future efforts towards the development of more targeted treatment strategies for EIAV. By understanding where the virus hides and thrives in the host body, scientists and clinicians can develop methods to specifically target these areas, enhancing the effectiveness of treatment options.

Cite This Article

APA
Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, Montelaro RC. (2000). Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol, 74(7), 3112-3121. https://doi.org/10.1128/jvi.74.7.3112-3121.2000

Publication

ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 74
Issue: 7
Pages: 3112-3121

Researcher Affiliations

Harrold, S M
  • Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Cook, S J
    Cook, R F
      Rushlow, K E
        Issel, C J
          Montelaro, R C

            MeSH Terms

            • Animals
            • Base Sequence
            • DNA Primers
            • DNA, Viral / analysis
            • Equine Infectious Anemia / virology
            • Horses
            • Infectious Anemia Virus, Equine / genetics
            • Infectious Anemia Virus, Equine / physiology
            • RNA Splicing
            • RNA, Viral / analysis
            • RNA, Viral / genetics
            • Reverse Transcriptase Polymerase Chain Reaction
            • Virus Replication

            Grant Funding

            • R01 CA049296 / NCI NIH HHS
            • T32 AI007487 / NIAID NIH HHS
            • R01 CA49296 / NCI NIH HHS
            • 5T32 AI07487 / NIAID NIH HHS
            • P41 RR006009 / NCRR NIH HHS
            • 2 P41 RR06009 / NCRR NIH HHS

            References

            This article includes 48 references
            1. Bagnarelli P, Menzo S, Valenza A, Manzin A, Giacca M, Ancarani F, Scalise G, Varaldo PE, Clementi M. Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS.. J Virol 1992 Dec;66(12):7328-35.
            2. Bagnarelli P, Valenza A, Menzo S, Sampaolesi R, Varaldo PE, Butini L, Montroni M, Perno CF, Aquaro S, Mathez D, Leibowitch J, Balotta C, Clementi M. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo.. J Virol 1996 Nov;70(11):7603-13.
            3. Chong YH, Payne SL, Issel CJ, Montelaro RC, Rushlow KE. Characterization of the antigenic domains of the major core protein (p26) of equine infectious anemia virus.. J Virol 1991 Feb;65(2):1007-12.
            4. Clements JE, Zink MC. Molecular biology and pathogenesis of animal lentivirus infections.. Clin Microbiol Rev 1996 Jan;9(1):100-17.
              pmc: PMC172884pubmed: 8665473doi: 10.1128/CMR.9.1.100google scholar: lookup
            5. Crawford TB, Wardrop KJ, Tornquist SJ, Reilich E, Meyers KM, McGuire TC. A primary production deficit in the thrombocytopenia of equine infectious anemia.. J Virol 1996 Nov;70(11):7842-50.
            6. Cunningham TP, Montelaro RC, Rushlow KE. Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors.. Gene 1993 Feb 14;124(1):93-8.
              pubmed: 8382658doi: 10.1016/0378-1119(93)90766-vgoogle scholar: lookup
            7. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.. Nature 1993 Mar 25;362(6418):359-62.
              pubmed: 8096068doi: 10.1038/362359a0google scholar: lookup
            8. Gendelman HE, Narayan O, Kennedy-Stoskopf S, Kennedy PG, Ghotbi Z, Clements JE, Stanley J, Pezeshkpour G. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages.. J Virol 1986 Apr;58(1):67-74.
              pmc: PMC252877pubmed: 3005660doi: 10.1128/JVI.58.1.67-74.1986google scholar: lookup
            9. Gendelman HE, Narayan O, Molineaux S, Clements JE, Ghotbi Z. Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow.. Proc Natl Acad Sci U S A 1985 Oct;82(20):7086-90.
              pmc: PMC391315pubmed: 2996004doi: 10.1073/pnas.82.20.7086google scholar: lookup
            10. Genetics Computer Group. Program manual for the Wisconsin Package. Madison, Wis: Genetics Computer Group; 1994.
            11. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.. J Virol 1997 May;71(5):3840-52.
            12. Issel CJ, Adams WV Jr, Meek L, Ochoa R. Transmission of equine infectious anemia virus from horses without clinical signs of disease.. J Am Vet Med Assoc 1982 Feb 1;180(3):272-5.
              pubmed: 6276353
            13. Kim CH, Casey JW. Genomic variation and segregation of equine infectious anemia virus during acute infection.. J Virol 1992 Jun;66(6):3879-82.
            14. Kim CH, Casey JW. In vivo replicative status and envelope heterogeneity of equine infectious anemia virus in an inapparent carrier.. J Virol 1994 Apr;68(4):2777-80.
            15. Klaus G G B, editor. Lymphocytes: a practical approach. Oxford, England: IRL Press, Ltd.; 1987.
            16. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.. Natl Inst Anim Health Q (Tokyo) 1976 Spring;16(1):8-15.
              pubmed: 177894
            17. Kono Y, Kobayashi K, Fukunaga Y. Distribution of equine infectious anemia virus in horses infected with the virus.. Natl Inst Anim Health Q (Tokyo) 1971 Spring;11(1):11-20.
              pubmed: 4325551
            18. Langemeier JL, Cook SJ, Cook RF, Rushlow KE, Montelaro RC, Issel CJ. Detection of equine infectious anemia viral RNA in plasma samples from recently infected and long-term inapparent carrier animals by PCR.. J Clin Microbiol 1996 Jun;34(6):1481-7.
            19. Lichtenstein DL, Rushlow KE, Cook RF, Raabe ML, Swardson CJ, Kociba GJ, Issel CJ, Montelaro RC. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.. J Virol 1995 May;69(5):2881-8.
            20. Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, Wiltrout TA, Brown C, Schneider D, Wahl L, Lloyd AL, Williams J, Elkins WR, Fauci AS, Hirsch VM. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.. J Virol 1997 Dec;71(12):9508-14.
            21. Maury W. Monocyte maturation controls expression of equine infectious anemia virus.. J Virol 1994 Oct;68(10):6270-9.
            22. Maury W, Oaks JL, Bradley S. Equine endothelial cells support productive infection of equine infectious anemia virus.. J Virol 1998 Nov;72(11):9291-7.
            23. McGuire TC, Crawford TB, Henson JB. Immunofluorescent localization of equine infectious anemia virus in tissue.. Am J Pathol 1971 Feb;62(2):283-94.
              pmc: PMC2047532pubmed: 4322275
            24. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease.. J Virol 1992 Jan;66(1):310-6.
              pmc: PMC238289pubmed: 1727491doi: 10.1128/JVI.66.1.310-316.1992google scholar: lookup
            25. Montelaro R C, Ball J M, Rushlow K E. Equine retroviruses. In: Levy J A, editor. The Retroviridae. Vol. 2. New York, N.Y: Plenum Press; 1993. pp. 257u2013360.
            26. Oaks JL, McGuire TC, Ulibarri C, Crawford TB. Equine infectious anemia virus is found in tissue macrophages during subclinical infection.. J Virol 1998 Sep;72(9):7263-9.
            27. O'Rourke KI, Besola ML, McGuire TC. Proviral sequences detected by polymerase chain reaction in peripheral blood cells of horses with equine infectious anemia lentivirus.. Arch Virol 1991;117(1-2):109-19.
              pubmed: 1848747doi: 10.1007/BF01310496google scholar: lookup
            28. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.. Nature 1993 Mar 25;362(6418):355-8.
              pubmed: 8455722doi: 10.1038/362355a0google scholar: lookup
            29. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
            30. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.. Science 1993 Mar 19;259(5102):1749-54.
              pubmed: 8096089doi: 10.1126/science.8096089google scholar: lookup
            31. Raabe ML, Issel CJ, Cook SJ, Cook RF, Woodson B, Montelaro RC. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.. Virology 1998 May 25;245(1):151-62.
              pubmed: 9614876doi: 10.1006/viro.1998.9142google scholar: lookup
            32. Raabe MR, Issel CJ, Montelaro RC. Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus.. J Virol Methods 1998 Mar;71(1):87-104.
              pubmed: 9628225doi: 10.1016/s0166-0934(97)00204-8google scholar: lookup
            33. Rasty S, Dhruva BR, Schiltz RL, Shih DS, Issel CJ, Montelaro RC. Proviral DNA integration and transcriptional patterns of equine infectious anemia virus during persistent and cytopathic infections.. J Virol 1990 Jan;64(1):86-95.
              pmc: PMC249051pubmed: 2152836doi: 10.1128/JVI.64.1.86-95.1990google scholar: lookup
            34. Reinhart TA, Rogan MJ, Huddleston D, Rausch DM, Eiden LE, Haase AT. Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS.. J Infect Dis 1997 Nov;176(5):1198-208.
              pubmed: 9359719doi: 10.1086/514113google scholar: lookup
            35. Rice NR, Lequarre AS, Casey JW, Lahn S, Stephens RM, Edwards J. Viral DNA in horses infected with equine infectious anemia virus.. J Virol 1989 Dec;63(12):5194-200.
            36. Rice NR, Simek S, Ryder OA, Coggins L. Detection of proviral DNA in horse cells infected with equine infectious anemia virus.. J Virol 1978 Jun;26(3):577-83.
              pmc: PMC525883pubmed: 209211doi: 10.1128/JVI.26.3.577-583.1978google scholar: lookup
            37. Rudolph JA, Spier SJ, Byrns G, Rojas CV, Bernoco D, Hoffman EP. Periodic paralysis in quarter horses: a sodium channel mutation disseminated by selective breeding.. Nat Genet 1992 Oct;2(2):144-7.
              pubmed: 1338908doi: 10.1038/ng1092-144google scholar: lookup
            38. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).. Arch Virol 1990;111(3-4):275-80.
              pubmed: 1693846doi: 10.1007/BF01311062google scholar: lookup
            39. Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, Pavlakis GN. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals.. AIDS Res Hum Retroviruses 1996 Oct 10;12(15):1443-56.
              pubmed: 8893052doi: 10.1089/aid.1996.12.1443google scholar: lookup
            40. Sambrook J, Fritsch E F, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press; 1989.
            41. Sellon DC, Fuller FJ, McGuire TC. The immunopathogenesis of equine infectious anemia virus.. Virus Res 1994 May;32(2):111-38.
              pmc: PMC7134051pubmed: 8067050doi: 10.1016/0168-1702(94)90038-8google scholar: lookup
            42. Sellon DC, Perry ST, Coggins L, Fuller FJ. Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes.. J Virol 1992 Oct;66(10):5906-13.
            43. Sellon DC, Walker KM, Russell KE, Perry ST, Covington P, Fuller FJ. Equine infectious anemia virus replication is upregulated during differentiation of blood monocytes from acutely infected horses.. J Virol 1996 Jan;70(1):590-4.
              pmc: PMC189850pubmed: 8523576doi: 10.1128/JVI.70.1.590-594.1996google scholar: lookup
            44. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.. J Virol 1990 Feb;64(2):864-72.
              pmc: PMC249182pubmed: 2296085doi: 10.1128/JVI.64.2.864-872.1990google scholar: lookup
            45. Smith B P. Large animal internal medicine. Diseases of horses, cattle, sheep, and goats. St. Louis, Mo: C.V. Mosby Co.; 1990.
            46. Swardson CJ, Lichtenstein DL, Wang S, Montelaro RC, Kociba GJ. Infection of bone marrow macrophages by equine infectious anemia virus.. Am J Vet Res 1997 Dec;58(12):1402-7.
              pubmed: 9401688
            47. Tornquist SJ, Oaks JL, Crawford TB. Elevation of cytokines associated with the thrombocytopenia of equine infectious anaemia.. J Gen Virol 1997 Oct;78 ( Pt 10):2541-8.
              pubmed: 9349475doi: 10.1099/0022-1317-78-10-2541google scholar: lookup
            48. Tumas DB, Hines MT, Perryman LE, Davis WC, McGuire TC. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses.. J Gen Virol 1994 May;75 ( Pt 5):959-68.
              pubmed: 7513746doi: 10.1099/0022-1317-75-5-959google scholar: lookup

            Citations

            This article has been cited 30 times.
            1. Karagianni AE, Eaton SL, Kurian D, Cillu00e1n-Garcia E, Twynam-Perkins J, Raper A, Wishart TM, Pirie RS. Application across species of a one health approach to liquid sample handling for respiratory based -omics analysis.. Sci Rep 2021 Jul 12;11(1):14292.
              doi: 10.1038/s41598-021-93839-9pubmed: 34253818google scholar: lookup
            2. Han X, Zhang P, Yu W, Xiang W, Li X. Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.. Virus Genes 2016 Dec;52(6):814-822.
              doi: 10.1007/s11262-016-1382-2pubmed: 27572122google scholar: lookup
            3. Liu Q, Ma J, Wang XF, Xiao F, Li LJ, Zhang JE, Lin YZ, Du C, He XJ, Wang X, Zhou JH. Infection with equine infectious anemia virus vaccine strain EIAVDLV121 causes no visible histopathological lesions in target organs in association with restricted viral replication and unique cytokine response.. Vet Immunol Immunopathol 2016 Feb;170:30-40.
              doi: 10.1016/j.vetimm.2016.01.006pubmed: 26832985google scholar: lookup
            4. Liu Q, Wang XF, Ma J, He XJ, Wang XJ, Zhou JH. Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome.. Viruses 2015 Jun 19;7(6):3241-60.
              doi: 10.3390/v7062769pubmed: 26102582google scholar: lookup
            5. Du C, Ma J, Liu Q, Li YF, He XJ, Lin YZ, Wang XF, Meng QW, Wang X, Zhou JH. Mice transgenic for equine cyclin T1 and ELR1 are susceptible to equine infectious anemia virus infection.. Retrovirology 2015 Apr 28;12:36.
              doi: 10.1186/s12977-015-0163-7pubmed: 25928027google scholar: lookup
            6. Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.. PLoS Pathog 2015 Jan;11(1):e1004610.
              doi: 10.1371/journal.ppat.1004610pubmed: 25569288google scholar: lookup
            7. Liu C, Cook SJ, Craigo JK, Cook FR, Issel CJ, Montelaro RC, Horohov DW. Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.. Vet Immunol Immunopathol 2014 Oct 15;161(3-4):161-9.
              doi: 10.1016/j.vetimm.2014.08.001pubmed: 25176006google scholar: lookup
            8. Ma J, Wang SS, Lin YZ, Liu HF, Liu Q, Wei HM, Wang XF, Wang YH, Du C, Kong XG, Zhou JH, Wang X. Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.. Vet Res 2014 Aug 9;45(1):82.
              doi: 10.1186/s13567-014-0082-ypubmed: 25106750google scholar: lookup
            9. Craigo JK, Montelaro RC. Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.. Viruses 2013 Dec 2;5(12):2963-76.
              doi: 10.3390/v5122963pubmed: 24316675google scholar: lookup
            10. Bolfa P, Nolf M, Cadoru00e9 JL, Catoi C, Archer F, Dolmazon C, Mornex JF, Leroux C. Interstitial lung disease associated with Equine Infectious Anemia Virus infection in horses.. Vet Res 2013 Dec 1;44(1):113.
              doi: 10.1186/1297-9716-44-113pubmed: 24289102google scholar: lookup
            11. Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC. Envelope determinants of equine lentiviral vaccine protection.. PLoS One 2013;8(6):e66093.
              doi: 10.1371/journal.pone.0066093pubmed: 23785473google scholar: lookup
            12. Issel CJ, Scicluna MT, Cook SJ, Cook RF, Caprioli A, Ricci I, Rosone F, Craigo JK, Montelaro RC, Autorino GL. Challenges and proposed solutions for more accurate serological diagnosis of equine infectious anaemia.. Vet Rec 2013 Feb 23;172(8):210.
              doi: 10.1136/vr-2012-100735pubmed: 23161812google scholar: lookup
            13. Craigo JK, Ezzelarab C, Montelaro RC. Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.. J Virol Methods 2012 Nov;185(2):221-7.
            14. Patel JR, Heldens JG, Bakonyi T, Rusvai M. Important mammalian veterinary viral immunodiseases and their control.. Vaccine 2012 Feb 27;30(10):1767-81.
              doi: 10.1016/j.vaccine.2012.01.014pubmed: 22261411google scholar: lookup
            15. Cappelli K, Capomaccio S, Cook FR, Felicetti M, Marenzoni ML, Coppola G, Verini-Supplizi A, Coletti M, Passamonti F. Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.. J Clin Microbiol 2011 Jan;49(1):27-33.
              doi: 10.1128/JCM.01311-10pubmed: 21084503google scholar: lookup
            16. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC. Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.. Vaccine 2010 Nov 29;28(51):8095-104.
              doi: 10.1016/j.vaccine.2010.10.003pubmed: 20955830google scholar: lookup
            17. Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, Issel CJ, Montelaro RC. An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.. Retrovirology 2009 Oct 20;6:95.
              doi: 10.1186/1742-4690-6-95pubmed: 19843328google scholar: lookup
            18. Fidalgo-Carvalho I, Craigo JK, Barnes S, Costa-Ramos C, Montelaro RC. Characterization of an equine macrophage cell line: application to studies of EIAV infection.. Vet Microbiol 2009 Apr 14;136(1-2):8-19.
              doi: 10.1016/j.vetmic.2008.10.010pubmed: 19038510google scholar: lookup
            19. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.. J Virol 2008 Dec;82(23):11889-901.
              doi: 10.1128/JVI.01537-08pubmed: 18818324google scholar: lookup
            20. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy.. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
              doi: 10.1073/pnas.0706449104pubmed: 17846425google scholar: lookup
            21. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.. Vaccine 2007 Jan 15;25(5):834-45.
              doi: 10.1016/j.vaccine.2006.09.040pubmed: 17023099google scholar: lookup
            22. Fraser DG, Leib SR, Zhang BS, Mealey RH, Brown WC, McGuire TC. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.. Clin Diagn Lab Immunol 2005 Aug;12(8):983-93.
            23. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.. J Virol 2005 Mar;79(5):2666-77.
            24. Baccam P, Thompson RJ, Li Y, Sparks WO, Belshan M, Dorman KS, Wannemuehler Y, Oaks JL, Cornette JL, Carpenter S. Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.. J Virol 2003 Nov;77(22):12122-31.
            25. Fraser DG, Mealey RH, McGuire TC. Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.. Immunogenetics 2003 Oct;55(7):508-14.
              doi: 10.1007/s00251-003-0600-ypubmed: 12942208google scholar: lookup
            26. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.. J Virol 2003 Jul;77(13):7244-53.
            27. Howe L, Leroux C, Issel CJ, Montelaro RC. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.. J Virol 2002 Nov;76(21):10588-97.
            28. Fraser DG, Oaks JL, Brown WC, McGuire TC. Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus.. Immunology 2002 Mar;105(3):295-305.
            29. Leroux C, Craigo JK, Issel CJ, Montelaro RC. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.. J Virol 2001 May;75(10):4570-83.
            30. Hammond SA, Li F, McKeon BM Sr, Cook SJ, Issel CJ, Montelaro RC. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.. J Virol 2000 Jul;74(13):5968-81.